JP2008530171A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530171A5 JP2008530171A5 JP2007555581A JP2007555581A JP2008530171A5 JP 2008530171 A5 JP2008530171 A5 JP 2008530171A5 JP 2007555581 A JP2007555581 A JP 2007555581A JP 2007555581 A JP2007555581 A JP 2007555581A JP 2008530171 A5 JP2008530171 A5 JP 2008530171A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- diaza
- cycloalkyl
- bicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- -1 cyano, amino Chemical group 0.000 claims 7
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000004952 trihaloalkoxy group Chemical group 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 6
- 230000036407 pain Effects 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- IHORRZGYUBPGCG-IRXDYDNUSA-N (1s,4s)-5-methyl-2-[5-(2-phenylethynyl)pyrazin-2-yl]-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(N=C1)=CN=C1C#CC1=CC=CC=C1 IHORRZGYUBPGCG-IRXDYDNUSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- OPBXCDZGUWLYPX-HOTGVXAUSA-N (1s,4s)-2-[6-(2-phenylethynyl)pyridazin-3-yl]-2,5-diazabicyclo[2.2.1]heptane Chemical class C([C@]1(NC[C@]2([H])C1)[H])N2C(N=N1)=CC=C1C#CC1=CC=CC=C1 OPBXCDZGUWLYPX-HOTGVXAUSA-N 0.000 claims 1
- YOECRSJRTOCTON-IRXDYDNUSA-N (1s,4s)-2-[6-[2-(4-fluorophenyl)ethynyl]pyridazin-3-yl]-5-methyl-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(N=N1)=CC=C1C#CC1=CC=C(F)C=C1 YOECRSJRTOCTON-IRXDYDNUSA-N 0.000 claims 1
- IUCDLGGPJGKCQM-IRXDYDNUSA-N (1s,4s)-2-[6-[2-(4-methoxyphenyl)ethynyl]pyridazin-3-yl]-5-methyl-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(N=N1)=CC=C1C#CC1=CC=C(OC)C=C1 IUCDLGGPJGKCQM-IRXDYDNUSA-N 0.000 claims 1
- ZKGGRRBNACKMTO-KBPBESRZSA-N (1s,4s)-2-[6-[2-(furan-2-yl)ethynyl]pyridazin-3-yl]-5-methyl-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(N=N1)=CC=C1C#CC1=CC=CO1 ZKGGRRBNACKMTO-KBPBESRZSA-N 0.000 claims 1
- GBIWSNIWMVHWRU-GJZGRUSLSA-N (1s,4s)-2-[6-[2-(furan-3-yl)ethynyl]pyridazin-3-yl]-5-methyl-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(N=N1)=CC=C1C#CC=1C=COC=1 GBIWSNIWMVHWRU-GJZGRUSLSA-N 0.000 claims 1
- CNWFKJRIWLFFRB-ROUUACIJSA-N (1s,4s)-5-methyl-2-[5-(2-phenylethynyl)pyridin-2-yl]-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(N=C1)=CC=C1C#CC1=CC=CC=C1 CNWFKJRIWLFFRB-ROUUACIJSA-N 0.000 claims 1
- XZYPBDMPPLMZAB-IRXDYDNUSA-N (1s,4s)-5-methyl-2-[5-(2-phenylethynyl)pyrimidin-2-yl]-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(N=C1)=NC=C1C#CC1=CC=CC=C1 XZYPBDMPPLMZAB-IRXDYDNUSA-N 0.000 claims 1
- RSCTUBBFJQLINO-IRXDYDNUSA-N (1s,4s)-5-methyl-2-[6-(2-phenylethynyl)pyridazin-3-yl]-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(N=N1)=CC=C1C#CC1=CC=CC=C1 RSCTUBBFJQLINO-IRXDYDNUSA-N 0.000 claims 1
- JMPBASDMFIFLJA-KBPBESRZSA-N (1s,4s)-5-methyl-2-[6-(2-thiophen-2-ylethynyl)pyridazin-3-yl]-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(N=N1)=CC=C1C#CC1=CC=CS1 JMPBASDMFIFLJA-KBPBESRZSA-N 0.000 claims 1
- JBNDLGCOHLPZQH-GJZGRUSLSA-N (1s,4s)-5-methyl-2-[6-(2-thiophen-3-ylethynyl)pyridazin-3-yl]-2,5-diazabicyclo[2.2.1]heptane Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(N=N1)=CC=C1C#CC=1C=CSC=1 JBNDLGCOHLPZQH-GJZGRUSLSA-N 0.000 claims 1
- GFXRQCDJDMGVLX-KBPBESRZSA-N 2-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-(2-phenylethynyl)-1,3,4-thiadiazole Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(S1)=NN=C1C#CC1=CC=CC=C1 GFXRQCDJDMGVLX-KBPBESRZSA-N 0.000 claims 1
- CQKQYAVFNBQHGU-ROUUACIJSA-N 5-[2-[6-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]pyridazin-3-yl]ethynyl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C#CC2=CC=C(N=N2)N2C[C@]3(N(C[C@]2([H])C3)C)[H])=C1 CQKQYAVFNBQHGU-ROUUACIJSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010041247 Social fear Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 210000004246 corpus luteum Anatomy 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- UXAWXZDXVOYLII-UHFFFAOYSA-N tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)CC1NC2 UXAWXZDXVOYLII-UHFFFAOYSA-N 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200500229 | 2005-02-16 | ||
| US65351205P | 2005-02-17 | 2005-02-17 | |
| PCT/EP2006/050873 WO2006087305A1 (en) | 2005-02-16 | 2006-02-13 | Novel diazabicyclic aryl derivatives and their medical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008530171A JP2008530171A (ja) | 2008-08-07 |
| JP2008530171A5 true JP2008530171A5 (enExample) | 2009-04-02 |
Family
ID=36283929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555581A Abandoned JP2008530171A (ja) | 2005-02-16 | 2006-02-13 | 新規なジアザ二環系アリール誘導体及びそれらの医療上の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7750011B2 (enExample) |
| EP (1) | EP1866314B1 (enExample) |
| JP (1) | JP2008530171A (enExample) |
| AT (1) | ATE481407T1 (enExample) |
| DE (1) | DE602006016926D1 (enExample) |
| WO (1) | WO2006087305A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| PE20060437A1 (es) * | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) * | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0521508D0 (en) * | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GEP20125425B (en) * | 2006-10-18 | 2012-03-26 | Pfizer Prod Inc | Biaryl ether urea compounds |
| JP2011504909A (ja) * | 2007-11-30 | 2011-02-17 | ノイロサーチ アクティーゼルスカブ | 新規なカルボン酸４−フェニルアゾ−フェニルエステル誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのそれらの使用 |
| EP2670744B1 (en) | 2011-02-03 | 2015-05-27 | Lupin Limited | Pyrrole derivatives used as modulators of alpha7 nachr |
| AU2012221800B2 (en) | 2011-02-23 | 2016-10-27 | Lupin Limited | Heteroaryl derivatives as alpha7 nAChR modulators |
| AU2012235779B2 (en) | 2011-03-31 | 2017-03-02 | Lupin Limited | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease |
| ES2606043T3 (es) | 2011-07-05 | 2017-03-17 | Lupin Limited | Derivados de biarilo como moduladores de nAChR |
| WO2013132380A1 (en) | 2012-03-06 | 2013-09-12 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| WO2014072957A1 (en) | 2012-11-12 | 2014-05-15 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| US9617211B2 (en) | 2013-01-16 | 2017-04-11 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| US9617210B2 (en) | 2013-03-13 | 2017-04-11 | Lupin Limited | Pyrrole derivatives as alpha 7 NACHR modulators |
| TW201446243A (zh) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
| WO2014203150A1 (en) | 2013-06-17 | 2014-12-24 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
| KR102218333B1 (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| CN114409669B (zh) * | 2022-01-24 | 2023-06-23 | 云南民族大学 | 一种氧杂降冰片烯环上c-5位炔基取代的斑蝥素衍生物及其制备方法与应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478939A (en) | 1994-07-20 | 1995-12-26 | American Cyanamid Company | (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives |
| GB9803411D0 (en) | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
| FR2786769B1 (fr) | 1998-12-04 | 2002-10-25 | Synthelabo | Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique |
| EP1147112B1 (en) | 1999-01-29 | 2003-10-29 | Abbott Laboratories | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands |
| MXPA04010966A (es) | 2002-05-07 | 2005-01-25 | Neurosearch As | Derivados novedosos de biarilo diazabiciclico. |
| DE60311853T2 (de) | 2002-09-30 | 2007-06-21 | Neurosearch A/S | Neue 1,4-diazabicycloalkanderivate, deren herstellung und verwendung |
| EP1562945B1 (en) | 2002-11-11 | 2006-11-15 | Neurosearch A/S | 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof |
| WO2005011654A2 (en) * | 2003-07-29 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
| KR20060037409A (ko) | 2003-07-30 | 2006-05-03 | 제논 파마슈티칼스 인크. | 피페라진 유도체 및 그의 치료제로서의 용도 |
| KR20060125885A (ko) | 2004-02-04 | 2006-12-06 | 뉴로서치 에이/에스 | 콜린 수용체 조절제로서의 디아자바이사이클릭 아릴 유도체 |
-
2006
- 2006-02-13 EP EP06708215A patent/EP1866314B1/en not_active Expired - Lifetime
- 2006-02-13 JP JP2007555581A patent/JP2008530171A/ja not_active Abandoned
- 2006-02-13 AT AT06708215T patent/ATE481407T1/de not_active IP Right Cessation
- 2006-02-13 US US11/884,345 patent/US7750011B2/en not_active Expired - Fee Related
- 2006-02-13 WO PCT/EP2006/050873 patent/WO2006087305A1/en not_active Ceased
- 2006-02-13 DE DE602006016926T patent/DE602006016926D1/de not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008530172A5 (enExample) | ||
| US8017631B2 (en) | Oxadiazole derivatives and their medical use | |
| JP2009538867A5 (enExample) | ||
| US20100029685A1 (en) | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators | |
| JP2009526776A5 (enExample) | ||
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| JP2009538869A5 (enExample) | ||
| JP2008539195A5 (enExample) | ||
| CA2389553A1 (en) | Heteroaryl-diazabicycloalkanes | |
| JP2009537599A5 (enExample) | ||
| JP2009538870A5 (enExample) | ||
| JP2008517032A5 (enExample) | ||
| JP2007520526A (ja) | コリン作動性受容体モジュレーターとしてのジアザビシクロアリール誘導体 | |
| JP2006508109A (ja) | １，４−ジアザビシクロ（３，２，２）ノナン誘導体、その製造方法及びその使用 | |
| JP2009538868A (ja) | 新規な１，４−ジアザ−ビシクロ［３．２．２］ノニルピリミジニル誘導体及びその医学的使用 | |
| JP4995203B2 (ja) | 精神病および神経変性障害の処置のための、ｎ−ＡＣｈＲのコリン作動性リガンドとしての（１−アザ−ビシクロ［３．３．１］ノン−４−イル）−［５−（１Ｈ−インドール−５−イル）−ヘテロアリール］−アミン | |
| JP2006519208A (ja) | 新規ジアザビシクロアリール誘導体 | |
| JP2008530171A (ja) | 新規なジアザ二環系アリール誘導体及びそれらの医療上の使用 | |
| JP2008517032A (ja) | 新規なジアザ二環式アリール誘導体及びその医薬用途 | |
| JP2009537599A (ja) | 新規８，１０−ジアザ−ビシクロ［４．３．１］デカン誘導体及びそれらの医学的使用 | |
| JP2007520525A5 (enExample) | ||
| RU2008110911A (ru) | Новые диазабициклические арильные производные и их медицинское применение | |
| RU2010135035A (ru) | Новые триарильные производные, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| KR20050062575A (ko) | 신규한 1,4-디아자바이사이클로알칸 유도체, 이의 제법 및용도 | |
| JP2009526024A5 (enExample) |